qrxpharma announces strategic partnership with, page-8

Assuming $80m sales first year, $1.35 was about 2.5x earnings.
Assuming $100m sales first year, $1.60 is about 2.5x earnings.

I don't think $2 would be unreasonable if the stock market can just survive January next year!

These are just figures for MoxDuo IR. The CR product is still to come, as is distribution and marketing arrangements in Europe. I presume John can deliver on these, given the company's track record.

Beats me why it has taken so little volume to push the price around historically.